Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 8
Submit an article Journal homepage
454
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Joaquín Martínez-Lópeza Servicio de Hematología y Hemoterapia, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense de Madrid (UCM), Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7908-0063View further author information
ORCID Icon,
Satu Mustjokib Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland;c Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandORCID Iconhttps://orcid.org/0000-0002-0816-8241View further author information
ORCID Icon,
Kimmo Porkkac Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandView further author information
,
Rebecca B. Klisovicd Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USAView further author information
,
Dominik Wolfe Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria;f Medical Clinic 3, University Hospital Bonn, Bonn, GermanyView further author information
,
Lambert Busqueg Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada;h Department of Medicine, University of Montreal, Montreal, QC, CanadaView further author information
,
Juan Carlos Hernández-Boludai Hematology Department, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, SpainORCID Iconhttps://orcid.org/0000-0002-4289-3113View further author information
ORCID Icon,
Rene Swaninkj Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Patricia Martin Regueiraj Bristol Myers Squibb, Princeton, NJ, USAView further author information
&
Jeffrey H. Liptonk Princess Margaret Cancer Centre, Toronto, ON, CanadaView further author information
 show all
Pages 2040-2043 | Received 18 Aug 2020, Accepted 06 Feb 2021, Published online: 02 Mar 2021

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.